Request Consultation
Three CDMOs are booming across the biologics market, as Lonza explores its scientific innovation & end-to-end multimodality, while Samsung Biologics is facilitating huge industrial scale & turnkey implementation. Whereas Catalent blooms on highly flexible, localized drug product/fill-finish services.
The global biologics CDMO market size is calculated at USD 22 billion in 2024, grew to USD 25.41 billion in 2025, and is projected to reach around USD 92.79 billion by 2034. The market is expanding at a CAGR of 15.48% between 2025 and 2034. Respective expansion is fueled by surging demand for biologics, accelerating investments, & broadening R&D activities.
According to Towards Healthcare’s Biologics CDMO Market Size and Growth Rate Forecast 2034, increasing demand for biologics, like regenerative medicines, monoclonal antibodies, & vaccines, is widely demanding CDMO services.
Describing Comparison Among Lonza, Samsung Biologics, and Catalent Biologics CDMO
| Features | Lonza | Samsung Biologics | Catalent Biologics |
| Key Strength | A firm plays a pivotal role in Process development, technical depth, & different mammalian or microbial platforms | This leader has been executing incredible, massive commercial manufacturing capacity & plant construction pace. | Catalent has a broader global fill-finish network, advanced drug delivery, along with extensive unified supply chain. |
| Major Geographic Centers | Europe (HQ), the US, & Asia | South Korea (HQ), & progressing across the globe | North America (HQ), Europe, & Asia. |
| Specialized Modalities | Lonza highly offers Bioconjugates (ADCs), mRNA, and Cell & Gene Therapies (CGT) | A company specializes in next-gen modalities, like organoid screening services, and developing ADC platforms. | It has been bolstering complete viral vector development, CAR-T, & well-sophisticated cell therapy production. |
| Total Sales in 2025 | It has reached sales of CHF 6.5 billion in 2025 | In 2025, a firm recorded total revenue of KRW 4,557 billion. | Catalent is pursuing revenue of nearly $4.4 billion for its CDMO business before completing its acquisition by Novo Holdings. |
| Capacity Expansion in 2026 | Lonza is completely joining Genentech’s Vacaville, California, facility, with a vast 330,000 liters of mammalian bioreactor capacity. | Samsung Biologics is widening its active global capacity to a stunning 845,000 liters. | Its respective expansion is covering Novo Nordisk, which acquired three of Catalent’s crown-jewel fill-finish sites for $11 billion. |
Which Biologics CDMO Should Pharma & Biotech Companies Choose?
| Company | Best For | Why |
| Lonza | Complex biologics, cell & gene therapy (CGT), and innovative biotech startups | Strong scientific expertise, advanced process development, and diversified mammalian and microbial platforms |
| Samsung Biologics | Large-scale commercial biologics manufacturing | Massive production capacity, rapid facility expansion, and efficient large-volume manufacturing capabilities |
| Catalent | Fill-finish services and flexible global supply chain solutions | Broad global network, advanced drug delivery technologies, and integrated biologics supply chain support. |
Latest Revolutionary Announcements by Lonza, Samsung Biologics & Catalent Biologics
- In May 2026, Oxford Nanopore Technologies & Lonza unveiled an innovative technology approach to advance & speed up GMP quality control testing for mRNA therapeutics.
- In March 2026, Samsung Biologics collaborated with Eli Lilly and Company (Lilly) to develop a Lilly Gateway Labs (LGL) site in Korea.
- In March 2026, GelMEDIX Inc. & Catalent, Inc. partnered to access Catalent’s GMP-induced pluripotent stem cells (iPSCs) & Catalent’s cell therapy manufacturing expertise and capabilities to assist the progression & clinical production of GelMEDIX’s iPSC-derived cell therapies.
Future of Biologics CDMO Market: AI, ADCs, mRNA & Asia-Pacific Expansion (2026–2030)
Between 2026 and 2030, the biologics CDMO market is expected to witness rapid transformation through AI-driven biologics manufacturing, continuous production technologies, and rising personalized medicine demand. Increasing expansion in antibody-drug conjugates (ADCs), mRNA therapeutics, and cell therapies is accelerating outsourcing partnerships. Moreover, Asia-Pacific is emerging as a strategic biologics manufacturing hub due to cost advantages, infrastructure investments, and growing pharmaceutical innovation, significantly strengthening global biologics outsourcing and CDMO competitiveness.
About the Experts
Aditi Shivarkar
Aditi leads as Vice President at Towards Healthcare and brings over 15 years of experience in healthcare research, innovation, and strategy. She works closely with data from across the healthcare sector and turns it into clear direction that companies can actually use. Her work covers pharmaceuticals, medical devices, and digital health. She helps businesses understand where the market is going and how to respond with confidence. Aditi focuses on practical thinking, strong decision-making, and delivering real results that make a difference.
Aman Singh
Aman Singh brings over 13 years of experience in healthcare research and consulting. He studies global healthcare trends and keeps a close eye on areas like biotech, AI in healthcare, and new treatment approaches. At Towards Healthcare, he leads the research team and makes sure the work stays accurate, useful, and easy to understand. Aman breaks down complex changes in the industry and helps businesses make smart, informed decisions.
Piyush Pawar
Piyush Pawar works as Senior Manager for Sales and Business Growth at Towards Healthcare, with more than 10 years of experience in the healthcare space. He works directly with clients and helps them find the right research for their needs. He makes sure clients understand the insights and know how to use them in their business. Piyush builds strong relationships and focuses on helping companies grow by turning research into clear, practical action.
